Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376327 | 1.00 | CRBN (0.49) | CRBNDDB1MAOAHTR6KCNH2 | |
| SCHEMBL31443918 | 0.83 | CRBN (0.45) | CRBNDDB1HTR6 | |
| SCHEMBL22324894 | 0.81 | ALDH1A1 (0.43) | MAOAHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31444240 | 0.81 | CRBN (0.43) | CRBNDDB1HTR6SLC6A2SLC6A4 | |
| SCHEMBL31444046 | 0.81 | CRBN (0.43) | CRBNDDB1HTR6SLC6A2SLC6A4 | |
| SCHEMBL25169813 | 0.81 | DDB1 (0.43) | CRBNDDB1MAOA | |
| SCHEMBL30087087 | 0.80 | DDB1 (0.58) | CRBNDDB1HTR6 | |
| SCHEMBL22119597 | 0.80 | DDB1 (0.58) | CRBNDDB1HTR6 | |
| SCHEMBL26683763 | 0.79 | APP (0.47) | CRBNDDB1SLC6A4 | |
| SCHEMBL22144563 | 0.79 | CRBN (0.58) | CRBNDDB1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | CRBN 32/4885DDB1 425/4885MAOA 3084/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | CRBN 249/4885DDB1 368/4885MAOA 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.